Convalescent Plasma in Hospitalized COVID-19 Patients: a Single Center Experience
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- COVID-19
- Sponsor
- Azienda Socio Sanitaria Territoriale di Mantova
- Status
- No Longer Available
- Last Updated
- 2 years ago
Overview
Brief Summary
The study assesses the efficacy and safety of administration of hyperimmune plasma in hospitalized COVID-19 patients. Efficacy was measured as 28-day mortality following convalescent plasma transfusion. Safety was measured as the rate of adverse reactions. to plasma infusion.
Detailed Description
Inclusion criteria: Adult inpatients with a severe form of COVID-19 have been enrolled, with at least one of the following inclusion criteria: 1) tachypnea with respiratory rate (RR) \> 30 breaths/min; 2) oxygen saturation (SpO2) ≤ 93% at rest and in room air; 3) partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ≤ 200 mmHg, 4) radiological picture and/or chest CT scan showing signs of interstitial disease and/or rapid progression of lung involvement. Primary outcome: Overall mortality at 28 days after hospitalization Secondary outcome: Adverse reaction to plasma transfusion.
Investigators
Massimo Franchini
Director Immunohematology and Transfusion Center
Azienda Socio Sanitaria Territoriale di Mantova
Eligibility Criteria
Inclusion Criteria
- •Adult patients admitted for severe COVID-19
Exclusion Criteria
- •\< 18 years
- •participation in any other clinical trial of an experimental treatment for COVID-19
Outcomes
Primary Outcomes
Not specified